A. Eremeeva

Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults.

Andrey Pristrom, Nikolay Soroka, P. А. Shesternya et al. · PubMed · 2020 · 40 citations

THE RESULTS OF A PHASE III COMPARATIVE CLINICAL TRIAL OF RITUXIMAB (ACELLBIA® AND MABTHERA®) IN RHEUMATOID ARTHRITIS (THE BIORA STUDY)

E L Nasonov, L. A. Knyazeva, Mazurov Vi et al. · Rheumatology Science and Practice · 2016 · 31 citations · Full text

Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study

Mazurov Vi, I. Z. Gaydukova, A. Eremeeva et al. · Rheumatology Science and Practice · 2020 · 20 citations · Full text

Rheumatoid Disorder, Rheumatology, Anti-inflammatory +14

Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA

Mazurov Vi, I. Z. Gaydukova, N. Soroka et al. · Rheumatology Science and Practice · 2020 · 17 citations · Full text

Ntk Arm, Immunology, Pharmacotherapy +20

Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA

Mazurov Vi, I. Z. Gaydukova, N. Soroka et al. · Modern Rheumatology Journal · 2020 · 17 citations · Full text

Long-term Efficacy, Pharmacotherapy, Dermatology +20